SAB Biotherapeutics (SABS) Common Equity (2020 - 2026)

SAB Biotherapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $227.2 million for Q1 2026.

• Quarterly Common Equity rose 961.54% year-over-year to $227.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $227.2 million (up 961.54% YoY) and the FY2025 annual result came in at $151.5 million, up 483.35% from the prior year.
• Common Equity was $227.2 million for Q1 2026 at SAB Biotherapeutics, up from $151.5 million in the prior quarter.
• Across five years, Common Equity topped out at $227.2 million in Q1 2026 and bottomed at $12.0 million in Q2 2025.
• A 5-year average of $58.6 million and a median of $36.9 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2025 — Common Equity plunged 73.95% — and 2026, when it surged 961.54%.
• SAB Biotherapeutics' Common Equity stood at $31.1 million in 2022, then soared by 84.49% to $57.3 million in 2023, then tumbled by 54.68% to $26.0 million in 2024, then jumped by 483.35% to $151.5 million in 2025, then jumped by 50.0% to $227.2 million in 2026.
• Business Quant data shows SABS's Common Equity at $227.2 million in Q1 2026, $151.5 million in Q4 2025, and $165.1 million in Q3 2025.